MacroChem CEO To Present at BIO ``Emerging Company Investor Forum'' On October 15 In San Francisco.LEXINGTON, Mass. -- MacroChem Corporation (Nasdaq:MCHM) has announced that Robert DeLuccia, its president and chief executive officer, will present on the Company's technologies, products and business strategies at the "BIO Emerging Company Investor Forum" in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden on October 15. In his presentation, Mr. DeLuccia will review the business strategy of MacroChem, a specialty pharmaceutical company developing innovative products by capitalizing on its proprietary transdermal drug delivery technology, SEPA SEPA® Soft enhancer of percutaneous absorption Therapeutics A technology that enhances transdermal drug delivery. See Transcutaneous therapy. (R). He will also discuss the status of the company's two SEPA-enhanced products in clinical development - Opterone(R), a topical testosterone cream for treating male hypogonadism Noun 1. male hypogonadism - the state of being a eunuch (either because of lacking testicles or because they failed to develop) eunuchoidism hypogonadism - incompetence of the gonads (especially in the male with low testosterone); results in deficient , and EcoNail(TM), an econazole nail lacquer lacquer, solution of film-forming materials, natural or synthetic, usually applied as an ornamental or protective coating. Quick-drying synthetic lacquers are used to coat automobiles, furniture, textiles, paper, and metalware. for treating onychomycosis (fungal nail infections fungal nail infection Onychomycosis, see there ). This call is being webcast by CCBN CCBN Central Coast Bancorp CCBN Charles County Business Network and can be accessed at MacroChem's web site at www.macrochem.com The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com). The web address of MacroChem's presentation is http://www.corporate- ir.net/ireye/confLobby.zhtml?ticker=MCHM&item_id=949877 About MacroChem MacroChem is a specialty pharmaceutical company that innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. MacroChem is developing two products containing its patented enhancer, SEPA: Opterone(TM), a SEPA-enhanced topical treatment for men with testosterone deficiency; and EcoNail(TM), a SEPA- enhanced antifungal nail lacquer to treat a common and potentially debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction nail infection known as onychomycosis. With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward- looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements Capital requirements Financing required for the operation of a business, composed of long-term and working capital plus fixed assets. , financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion